Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey

Serkan Karahan,F. Katkat

DOI: https://doi.org/10.1007/s12603-020-1479-0

2020-10-05

Abstract:Because of the lack of sufficient data, we aimed to investigate the role of serum 25(OH) vitamin D level on COVID severity and related mortality.

nutrition & dietetics,geriatrics & gerontology,gerontology

What problem does this paper attempt to address?

Serum 25-hydroxyvitamin D levels and health outcomes of hospitalization owing to COVID-19: a retrospective cross-sectional study

Irina Metonidze,Nestan Bostoganashvili,Tamar Goderidze,David Tananashvili

DOI: https://doi.org/10.1177/03000605241271770

2024-08-30

Journal of International Medical Research

Abstract:Journal of International Medical Research, Volume 52, Issue 8, August 2024. ObjectiveWe investigated the role of serum 25(OH)D (25-hydroxyvitamin D) in COVID-related health outcomes.MethodsWe conducted a retrospective cross-sectional study using data of the National Center of Disease Control and Public Health, Georgia. We extracted patient data including length of hospital stay, transfer to the intensive care unit, requirement for oxygen therapy, treatment with glucocorticoids, and symptoms. After obtaining written informed consent, 384 individuals were enrolled. We divided participants into three groups according to 25(OH)D levels: group 1 = 25(OH)D 20 ng/mL (n = 160).ResultsThe odds ratio (OR) for hospitalization in group 1 versus group 2 was 8.7 (95% confidence interval [CI] 3.6–21.3) and 5.6 for group 1 versus 3 (95% CI 2.7–11.9). Regarding oxygen therapy, OR = 28.41 for group 1 versus 2 (95% CI 3.7–220.5) and OR = 5.2 for group 1 versus 3 (95% CI 1.9–14.1). Regarding treatment with glucocorticoids, OR = 3.7 for group 1 versus 2 (95% CI 1.1–12.5) and OR = 8.4 for group 1 versus 3 (95% CI 1.8–40.7).ConclusionCOVID-19-related morbidity was associated with decreased serum 25(OH)D levels. Future studies should investigate the potential role of vitamin D sufficiency in preventing SARS-CoV-2 infection and mortality.

pharmacology & pharmacy,medicine, research & experimental
The relationship between vitamin D deficiency and mortality in older adults before and during COVID-19 pandemic

Mahmut Esad Durmuş,Özgür Kara,Murat Kara,Tuğçe Cansu Kaya,Fatıma Edibe Şener,Merve Durmuş,Ahmet Sertçelik,Banu Çakır,Levent Özçakar

DOI: https://doi.org/10.1016/j.hrtlng.2022.09.007

Abstract:Background: Vitamin D is an essential fat-soluble vitamin thought to be associated with chronic diseases, mortality and COVID-19. Objective: To investigate the association between 25(OH) vitamin D levels and mortality of chronic diseases in subjects aged ≥65 years before and during COVID-19 pandemic. Methods: A single-center, retrospective study was performed using the hospital database of subjects aged 65 years and older who had undergone vitamin D measurement between 01.01.2019 and 31.12.2021. All patients with vitamin D measurement (N = 2155) were followed as a cohort from the date of serum vitamin D analysis through death date or 01.01.2022. Age, gender, chronic diseases, survival status, date of death of the deceased, laboratory values including complete blood count, liver/renal functions and 25(OH) vitamin D levels were all noted. Subjects were classified into three groups according to their 25(OH) vitamin D levels; severe deficient group (<10 ng/ml), moderate deficient group (10-19.9 ng/ml), and control group (≥20 ng/ml). Results: Data of 1949 subjects were included in this retrospective analysis and 206 of them (10.6%) had at least two vitamin D measurements. Until the time of data collection (01.01.2022), 94 of the cases had died within the last three years, and only five of them had repeated measurements. While the mean vitamin D level was lower, age and frequency of dyslipidemia, coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), arrhythmia, dementia and severe vitamin D deficiency (<10 ng/ml) were higher in subjectswho died (all p<0.05). According to the Cox proportional hazards model; age, presence of CAD, COPD, arrhythmia, dementia, anemia and severe vitamin D deficiency were independently related with mortality (all p<0.05). After adjusted by age, gender, and comorbidities, the probability of death was found to be 1.91 (95% CI=1.12-3.24) times higher in the severe vitamin D deficient group. Conclusions: The results of this study have shown that - after having adjusted for potential factors - severe vitamin D deficiency (<10 ng/ml) seems to be an independent predictor for non-cancer mortality. Although vitamin D measurement/treatment is very easy and cheap where, on the contrary, severe vitamin D deficiency can be quite mortal.
Serum vitamin D levels and the severity and clinical course of COVID-19

Mohamed Elnady,Ahmed Abdel Hafeez,Hebatallah Assal,Eman Zaid,Gihan Abo Elwafa

DOI: https://doi.org/10.4081/monaldi.2024.2978

2024-09-26

Abstract:Low vitamin D levels are associated with different pulmonary diseases, such as chronic obstructive pulmonary disease, bronchial asthma, and obstructive sleep apnea. In this study, we aimed to assess the relation between vitamin D levels and COVID-19 severity. Positive COVID-19 patients were subjected to clinical examination, computed tomography of the chest, and laboratory investigations. Serum vitamin D level was measured and correlated with the severity and the clinical course of the disease. The study included 72 patients, classified into four groups according to the severity of the disease. There was a statistically significant difference between the four groups regarding age, lymphocyte count, serum vitamin D, C-reactive protein, and lactate dehydrogenase levels. Serum vitamin D levels can be correlated with COVID-19 severity and clinical course.
The Impact of Serum Levels of Vitamin D3 and Its Metabolites on the Prognosis and Disease Severity of COVID-19

Hani M. J. Khojah,Sameh A. Ahmed,Sultan S. Al-Thagfan,Yaser M. Alahmadi,Yasser A. Abdou

DOI: https://doi.org/10.3390/nu14245329

IF: 5.9

2022-12-16

Nutrients

Abstract:Vitamin D is among the increasingly consumed dietary supplements during the COVID-19 pandemic. It plays a regulatory role in the immune system and moderates the renin–angiotensin system, which is implicated in infection pathogenesis. However, the investigation of serum levels of vitamin D3 forms and their relative ratios in COVID-19 patients is worth investigation to understand the impacts of disease severity. Hence, we investigated the serum levels of vitamin D3 (cholecalciferol) and its metabolites (calcifediol and calcitriol), in addition to their relative ratios and correlations with angiotensin-converting enzyme 2 (ACE2), interleukin-6 (Il-6), and neutrophil–lymphocyte ratio (NLR) in COVID-19 patients compared with healthy controls. Oropharyngeal specimens were collected from the study subjects for polymerase chain reaction testing for COVID-19. Whole blood samples were obtained for blood count and NLR testing, and sera were used for the analysis of the levels of the vitamin and its metabolites, ACE2, and IL-6. We enrolled 103 patients and 50 controls. ACE2, Il-6, and NLR were significantly higher in the patients group (72.37 ± 18.67 vs. 32.36 ± 11.27 U/L, 95.84 ± 25.23 vs. 2.76 ± 0.62 pg/mL, and 1.61 ± 0.30 vs. 1.07 ± 0.16, respectively). Cholecalciferol, calcifediol, and calcitriol were significantly lower in patients (18.50 ± 5.36 vs. 29.13 ± 4.94 ng/mL, 14.60 ± 3.30 vs. 23.10 ± 3.02 ng/mL, and 42.90 ± 8.44 vs. 65.15 ± 7.11 pg/mL, respectively). However, their relative ratios were normal in both groups. Levels of the vitamin and metabolites were strongly positively, strongly negatively, and moderately negatively correlated with ACE2, Il-6, and NLR, respectively. COVID-19 infection severity is associated with a significant decrease in vitamin D3 and its metabolites in a parallel pattern, and with a significant increase in ACE2, Il-6, and NLR. Higher levels of vitamin D and its metabolites are potentially protective against severe infection.

nutrition & dietetics
Vitamin D supplementations and mortality among patients with moderate/severe COVID-19: A meta-analysis of randomized controlled trials

Hyder Mirghani,Shamina Begum

DOI: https://doi.org/10.4103/jrms.jrms_591_23

2024-11-29

Journal of Research in Medical Sciences

Abstract:The most dramatic event of the current century is the COVID-19 pandemic. More than 617 million cases and 6.5 million death were confirmed globally until October 2022. [ 1 ] Importantly, worrisome new immune-evasive strains are discovered continuously, and one of the strains may cause a big wave, hospitalization, and mortality. [ 2 ] The challenge is the new strain with high transmission, severe presentation, and involvement of multiple organs including the heart, brain, and kidney. [ 3 ]

medicine, general & internal
Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection

Zhila Maghbooli,Mohammad Ali Sahraian,Mehdi Ebrahimi,Marzieh Pazoki,Samira Kafan,Hedieh Moradi Tabriz,Azar Hadadi,Mahnaz Montazeri,Mehrad Nasiri,Arash Shirvani,Michael F. Holick

DOI: https://doi.org/10.1371/journal.pone.0239799

IF: 3.7

2020-09-25

PLoS ONE

Abstract:To investigate the association between serum 25-hydroxyvitamin D levels and its effect on adverse clinical outcomes, and parameters of immune function and mortality due to a SARS-CoV-2 infection.The hospital data of 235 patients infected with COVID-19 were analyzed.Based on CDC criteria, among our study patients, 74% had severe COVID-19 infection and 32.8% were vitamin D sufficient. After adjusting for confounding factors, there was a significant association between vitamin D sufficiency and reduction in clinical severity, inpatient mortality serum levels of C-reactive protein (CRP) and an increase in lymphocyte percentage. Only 9.7% of patients older than 40 years who were vitamin D sufficient succumbed to the infection compared to 20% who had a circulating level of 25(OH)D< 30 ng/ml. The significant reduction in serum CRP, an inflammatory marker, along with increased lymphocytes percentage suggest that vitamin D sufficiency also may help modulate the immune response possibly by reducing risk for cytokine storm in response to this viral infection.Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.

multidisciplinary sciences
Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1

Mustafa Sait Gönen,Merve Alaylıoğlu,Emre Durcan,Yusuf Özdemir,Serdar Şahin,Dildar Konukoğlu,Okan Kadir Nohut,Seval Ürkmez,Berna Küçükece,İlker İnanç Balkan,H. Volkan Kara,Şermin Börekçi,Hande Özkaya,Zekayi Kutlubay,Yalım Dikmen,Yılmaz Keskindemirci,Spyridon N. Karras,Cedric Annweiler,Duygu Gezen-Ak,Erdinç Dursun

DOI: https://doi.org/10.3390/nu13114047

IF: 5.9

2021-11-12

Nutrients

Abstract:Background: We aimed to establish an acute treatment protocol to increase serum vitamin D, evaluate the effectiveness of vitamin D3 supplementation, and reveal the potential mechanisms in COVID-19. Methods: We retrospectively analyzed the data of 867 COVID-19 cases. Then, a prospective study was conducted, including 23 healthy individuals and 210 cases. A total of 163 cases had vitamin D supplementation, and 95 were followed for 14 days. Clinical outcomes, routine blood biomarkers, serum levels of vitamin D metabolism, and action mechanism-related parameters were evaluated. Results: Our treatment protocol increased the serum 25OHD levels significantly to above 30 ng/mL within two weeks. COVID-19 cases (no comorbidities, no vitamin D treatment, 25OHD <30 ng/mL) had 1.9-fold increased risk of having hospitalization longer than 8 days compared with the cases with comorbidities and vitamin D treatment. Having vitamin D treatment decreased the mortality rate by 2.14 times. The correlation analysis of specific serum biomarkers with 25OHD indicated that the vitamin D action in COVID-19 might involve regulation of INOS1, IL1B, IFNg, cathelicidin-LL37, and ICAM1. Conclusions: Vitamin D treatment shortened hospital stay and decreased mortality in COVID-19 cases, even in the existence of comorbidities. Vitamin D supplementation is effective on various target parameters; therefore, it is essential for COVID-19 treatment.

nutrition & dietetics
Association of Vitamin D Status and COVID-19-Related Hospitalization and Mortality

Karen H. Seal,Daniel Bertenthal,Evan Carey,Carl Grunfeld,Daniel D. Bikle,Chuanyi M. Lu

DOI: https://doi.org/10.1007/s11606-021-07170-0

IF: 5.7

2022-01-01

Journal of General Internal Medicine

Abstract:Abstract Background The relationship between vitamin D status and COVID-19-related clinical outcomes is controversial. Prior studies have been conducted in smaller, single-site, or homogeneous populations limiting adjustments for social determinants of health (race/ethnicity and poverty) common to both vitamin D deficiency and COVID-19 outcomes. Objective To evaluate the dose-response relationship between continuous 25(OH)D and risk for COVID-19-related hospitalization and mortality after adjusting for covariates associated with both vitamin D deficiency and COVID-19 outcomes. Design Retrospective cohort study. Patients Veteran patients receiving care in US Department of Veteran Affairs (VA) health care facilities with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test and a blood 25(OH)D test between February 20, 2020, and November 8, 2020, followed for up to 60 days. Main Measures Exposure was blood 25(OH)D concentration ascertained closest to and within 15 to 90 days preceding an index positive SARS-CoV-2 test. Co-primary study outcomes were COVID-19-related inpatient hospitalization requiring airborne, droplet, contact, or other isolation and mortality ascertained within 60 days of an index positive SARS-CoV-2 test. Key Results Of 4,599 veterans with a positive SARS-CoV-2 test, vitamin D deficiency (< 20 ng/mL) was identified in 665 (14.5%); 964 (21.0%) were hospitalized; and 340 (7.4%) died. After adjusting for all covariates, including race/ethnicity and poverty, there was a significant independent inverse dose-response relationship between increasing continuous 25(OH)D concentrations (from 15 to 60 ng/mL) and decreasing probability of COVID-19-related hospitalization (from 24.1 to 18.7%, p =0.009) and mortality (from 10.4 to 5.7%, p =0.001). In modeling 25(OH)D as a log-transformed continuous variable, the greatest risk for hospitalization and death was observed at lower 25(OH)D concentrations. Conclusions Continuous blood 25(OH)D concentrations are independently associated with COVID-19-related hospitalization and mortality in an inverse dose-response relationship in this large racially and ethnically diverse cohort of VA patients. Randomized controlled trials are needed to evaluate the impact of vitamin D supplementation on COVID-19-related outcomes.

medicine, general & internal,health care sciences & services
The impact of vitamin D administration on mortality in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials

Chia Siang Kow,Dinesh Sangarran Ramachandram,Syed Shahzad Hasan,Zhiyun Wong,Kaeshaelya Thiruchelvam

DOI: https://doi.org/10.1007/s10787-024-01564-2

2024-09-04

Inflammopharmacology

Abstract:Vitamin D, known for its role in bone health, is now being explored for its immunomodulatory effects. This study aimed to evaluate the impact of vitamin D supplementation on mortality in coronavirus disease 2019 (COVID-19) patients through a systematic review and meta-analysis of randomized controlled trials.

immunology,toxicology
Serum Vitamin D Concentrations and Covid-19 In Pregnant Women, Does Vitamin D Supplementation Impact Results? A Comprehensive Study

Mustafa ŞENGÜL,Halime ŞEN SELİM,Serhat ŞEN,Huriye ERBAK YILMAZ

DOI: https://doi.org/10.36516/jocass.1185181

2022-12-31

Cukurova Anestezi ve Cerrahi Bilimler Dergisi

Abstract:Aim: Low vitamin D levels were related to an increased risk of upper respiratory tract infection and pneumonia. Vitamin D might therefore protect against symptoms of the Covid 19. The present study aims to evaluate the relationship between the acquisition and course of Covid 19 and serum vitamin D levels and investigate the prophylactic efficacy of vitamin D supplementation in pregnant women. Materials and Methods: This case-control study was conducted on 318 pregnant women admitted to our tertiary clinic to give birth between March 2020 and December 2021. All cases were tested for Covid 19 via nasopharyngeal swab. Fifty-four patients with positive PCR for SARS-CoV-2 (Group 1) were matched with 264 consecutive healthy controls (Group 2). 25 OH D Vitamin levels were measured and compared between the two groups, along with the frequency of vitamin D supplementation. Results: Group 1 showed significantly low mean 25 OH D levels, compared to Group 2 (10,22 ± 7,10 (3-37)ng/ml vs. 16,63 ± 10,80 (3,40-48,90)ng/ml, p = 0,000). Sixteen point seven % of controls and 3,7% of cases had normal Vitamin D levels (>30 ng/mL); the difference was also statistically significant (p=0,005). The frequency of vitamin D supplementation was also detected higher in controls than those with positive SARS-CoV-2 (35,6% vs. 14,8%, p=0,003). Conclusions: Sustaining adequate levels of Vitamin D may positively impact protection against Covid 19 during pregnancy. In this context, Vitamin D supplementation should be considered for the pregnant population, particularly in settings where profound vitamin D deficiency is common.
Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection

José L Hernández,Daniel Nan,Marta Fernandez-Ayala,Mayte García-Unzueta,Miguel A Hernández-Hernández,Marcos López-Hoyos,Pedro Muñoz-Cacho,José M Olmos,Manuel Gutiérrez-Cuadra,Juan J Ruiz-Cubillán,Javier Crespo,Víctor M Martínez-Taboada

DOI: https://doi.org/10.1210/clinem/dgaa733

2020-10-27

Abstract:Abstract Background The role of vitamin D status in COVID-19 patients is a matter of debate. Objectives To assess serum 25-hydroxyvitamin D (25OHD) levels in hospitalized patients with COVID-19 and to analyze the possible influence of vitamin D status on disease severity. Methods Retrospective case–control study of 216 COVID-19 patients and 197 population-based controls. Serum 25OHD levels were measured in both groups. The association of serum 25OHD levels with COVID-19 severity (admission to the intensive care unit, requirements for mechanical ventilation, or mortality) was also evaluated. Results Of the 216 patients, 19 were on vitamin D supplements and were analyzed separately. In COVID-19 patients, mean ± standard deviation 25OHD levels were 13.8 ± 7.2 ng/mL, compared with 20.9 ± 7.4 ng/mL in controls (P < .0001). 25OHD values were lower in men than in women. Vitamin D deficiency was found in 82.2% of COVID-19 cases and 47.2% of population-based controls (P < .0001). 25OHD inversely correlates with serum ferritin (P = .013) and D-dimer levels (P = .027). Vitamin D-deficient COVID-19 patients had a greater prevalence of hypertension and cardiovascular diseases, raised serum ferritin and troponin levels, as well as a longer length of hospital stay than those with serum 25OHD levels ≥20 ng/mL. No causal relationship was found between vitamin D deficiency and COVID-19 severity as a combined endpoint or as its separate components. Conclusions 25OHD levels are lower in hospitalized COVID-19 patients than in population-based controls and these patients had a higher prevalence of deficiency. We did not find any relationship between vitamin D concentrations or vitamin deficiency and the severity of the disease.
Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients

Betsy Szeto,Jason E. Zucker,Elijah D. LaSota,Mishaela R. Rubin,Marcella D. Walker,Michael T. Yin,Adi Cohen

DOI: https://doi.org/10.1080/07435800.2020.1867162

2020-12-30

Endocrine Research

Abstract:<span><b>Context</b>: Populations severely affected by COVID-19 are also at risk for vitamin D deficiency. Common risk factors include older age, chronic illness, obesity, and non-Caucasian race. Vitamin D deficiency has been associated with risk for respiratory infections and failure, susceptibility and response to therapy for enveloped virus infection, and immune-mediated inflammatory reaction. <b>Objective</b>: To test the hypothesis that 25-hydroxyvitamin D[25(OH)D] deficiency is a risk factor for severity of COVID-19 respiratory and inflammatory complications. <b>Design</b>: We examined the relationship between prehospitalization 25(OH)D levels (obtained 1–365 days prior to admission) and COVID-19 clinical outcomes in 700 COVID-19 positive hospitalized patients. <b>Primary Outcomes</b>: Discharge status, mortality, length of stay, intubation status, renal replacement. <b>Secondary Outcomes</b>: Inflammatory markers. <b>Results</b>: 25(OH)D levels were available in 93 patients [25(OH)D:25(IQR:17–33)ng/mL]. Compared to those without 25(OH)D levels, those with measurements did not differ in age, BMI or distribution of sex and race, but were more likely to have comorbidities. Those with 25(OH)D < 20 ng/mL (n = 35) did not differ from those with 25(OH)D ≥ 20 ng/mL in terms of age, sex, race, BMI, or comorbidities. Low 25(OH)D tended to be associated with younger age and lower frequency of preexisting pulmonary disease. There were no significant between-group differences in any outcome. Results were similar in those ≥50 years, in male/female-only cohorts, and when differing 25(OH)D thresholds were used (<15 ng/mL and <30 ng/mL). There was no relationship between 25(OH)D as a continuous variable and any outcome, even after controlling for age and pulmonary disease. <b>Conclusions</b>: These preliminary data do not support a relationship between prehospitalization vitamin D status and COVID-19 clinical outcomes.</span>

endocrinology & metabolism
The role of vitamin D in outcomes of critical care in COVID-19 patients: Evidence from an umbrella meta-analysis of interventional and observational studies

Abdolreza Jamilian,Faezeh Ghalichi,Fatemeh Hamedi Kalajahi,Nima Radkhah,Neda Jourabchi,Vali Musazadeh,Ehsan Amini-Salehi,Meysam Zarezadeh,Alireza Ostadrahimi

DOI: https://doi.org/10.1017/s1368980024000934

2024-04-25

Public Health Nutrition

Abstract:Objectives: Several meta-analyses have suggested the beneficial effect of vitamin D on patients infected with SARS-CoV-2. This umbrella meta-analysis aims to evaluate influence of vitamin D supplementation on clinical outcomes and the mortality rate of COVID-19 patients. Design: Present study was designed as an umbrella meta-analysis. The following international databases were systematically searched till March 2023: Web of Science, PubMed, Scopus, and Embase. Settings: Random-effects model was employed to perform meta-analysis. Using AMSTAR critical evaluation tools, the methodological quality of the included meta-analyses was evaluated. Participants: Adult patients suffering from COVID-19 were studied. Results: Overall, 13 meta-analyses summarizing data from 4 RCTs and 9 observational studies were identified in this umbrella review. Our findings revealed that vitamin D supplementation and status significantly reduced mortality of COVID-19 [Interventional studies: (ES= 0.42; 95% CI: 0.10, 0.75, p <0.001; I 2 = 20.4%, p=0.285) and observational studies (ES= 1.99; 95% CI: 1.37, 2.62, p <0.001; I 2 = 00.0%, p=0.944). Also, vitamin D deficiency increased risk of infection and disease severity among patients. Conclusion: Overall, vitamin D status is a critical factor influencing the mortality rate, disease severity, admission to ICU and being detached from mechanical ventilation. It is vital to monitor the vitamin D status in all patients with critical conditions including COVID patients.

public, environmental & occupational health,nutrition & dietetics
Impact of Vitamin D Therapy on the Progress COVID-19: Six Weeks Follow-Up Study of Vitamin D Deficient Elderly Diabetes Patients

Amin R. Soliman,Tarek Samy Abdelaziz,Ahmed Fathy

DOI: https://doi.org/10.1177/20101058211041405

2021-09-01

Proceedings of Singapore Healthcare

Abstract:Background Coronavirus disease-19 (COVID-19) is an ongoing pandemic causing considerable fatalities worldwide. Vitamin D modulates the immune response through effects on various cells, such as: macrophages, B and T lymphocytes, neutrophils, and dendritic cells. Aim To explore whether supplementation of vitamin D, in the form of a single intramuscular cholecalciferol injection, to patients with diabetes, COVID-19, and low vitamin D levels could improve the prognosis of those patients. Methods This was a placebo-controlled randomized prospective study. The study has two arms as follows: the intervention arm (40 vitamin D deficient diabetes elderly patients that acquired SARS-CoV-2), compared to the control arm (16 elderly diabetes patients, with deficient vitamin D with SARS-CoV-2). Patients in the intervention arm were given vitamin D as a single intramuscular injection (200,000 IU); patients in the control arm were given placebo. The primary outcome was mortality within 6 weeks of the diagnosis of COVID-19. Clinical, laboratory, treatment, and outcome data were recorded after 6 weeks of follow-up. Results No significant difference in 6 weeks mortality was observed between patients who received vitamin D and patients who received placebo (17.5% vs 18.8%, p = 0.838). Age, presence of hypertension, and chronic obstructive pulmonary disease were independent predictors of mortality at 6 weeks. Conclusion Vitamin D supplementation did not reduce the severity or mortality of COVID-19 at 6 weeks. Further large scale studies are required to explore the effect of vitamin D therapy on survival in patients with diabetes mellitus who acquire COVID-19.
Risk factors for infection and mortality among hemodialysis patients during COVID-19 pandemic

Özgür Can,Gunal Bilek,Sibel Sahan

DOI: https://doi.org/10.1007/s11255-021-02926-3

IF: 2.2662

2021-07-05

International Urology and Nephrology

Abstract:<span class="a-plus-plus abstract-section id-a-sec1"><h3 class="a-plus-plus">Purpose</h3><p class="a-plus-plus">The aim of this study was to evaluate risk factors for COVID-19 infection and mortality and to document if any relation exists between 25 (OH) Vitamin D and COVID-19 infection.</p></span><span class="a-plus-plus abstract-section id-a-sec2"><h3 class="a-plus-plus">Methods</h3><p class="a-plus-plus">This retrospective study evaluated 151 HD patients. Patients infected with COVID-19 were compared to patients without the infection. Risk factors for intensive care unit (ICU) stay and mortality were analyzed. Deceased infected patients were also compared to patients who died due to other causes.</p></span><span class="a-plus-plus abstract-section id-a-sec3"><h3 class="a-plus-plus">Results</h3><p class="a-plus-plus">The mean age of all HD patients was 57.15 ± 15.73 years and 51.7% were male. The mean 25 (OH) Vitamin D level of all patients was 16.48 ± 8.45 ng/ml. Thirty-five infected patients were significantly older, had a higher Charlson comorbidity index (CCI) score. They also had a higher number of patients with diabetic nephropathy, cerebrovascular accident (CVA) and coronary heart disease (CHD). Patients who needed to stay in ICU had higher CCI score, a higher number of patients with diabetic nephropathy, pulmonary diseases and had statistically significantly higher CRP levels. Deceased infected patients were significantly older, had higher CCI scores and lower PTH than survived infected patients. Deceased infected patients had lower PTH, but had significantly lower leukocyte, lymphocyte counts and urea levels at admission when compared to patients who died due to other causes. Patients with poor prognosis had lower neutrophil and lymphocyte counts before infection and at admission; respectively. 25 (OH) Vitamin D level was not related to the risk of COVID-19 infection, ICU stay or mortality.</p></span><span class="a-plus-plus abstract-section id-a-sec4"><h3 class="a-plus-plus">Conclusion</h3><p class="a-plus-plus">Older age, higher CCI scores, diabetic nephropathy, CHD, CVA, pulmonary diseases, and lower neutrophil and lymphocyte counts were found as poor prognostic factors. The comparisons yielded no significant finding for 25 (OH) Vitamin D, acetylsalicylic acid, erythropoietin, intravenous iron, ACEI, ARBs, and dialysis adequacy parameters.</p></span>

urology & nephrology
Effects of Immunotoxicity biomarkers, essential elements and vitamin D levels on the severity levels of COVID-19 disease in Turkey

Jülide Secerlı,Serdar Çetinkaya,İlknur Sıla Leblebici,Latif Alperen Özdemir,Çiğdem Yücel,Eda Karaismailoğlu,Umut Kara,Aydan Özcan,Nesrin Öcal,Yakup Arslan,Serkan Şenkal,Onur Erdem,Merve Güdül Bacanlı

DOI: https://doi.org/10.1093/toxres/tfae177

2024-10-20

Abstract:Many mechanisms are thought to play a role in the pathogenesis of the COVID-19 pandemic, which started in 2019 and affected the whole world. It has been claimed that a deficiency in the immune system can significantly affect the severity of COVID-19 disease. It is important that the levels of essential elements and vitamin D are at certain levels for the healthy functioning of the immune system. Therefore, in this study, it was aimed to evaluate immunotoxicity biomarkers (tumor necrosis factor-alpha (TNF-α), interleukin (IL)-10, interferon (IFN)-γ, monocyte chemotactic protein-1 (MCP-1)), vitamin D, and essential element levels in COVID-19 patients in Turkey. According to the results of the study, it was found that the magnesium (Mg), zinc (Zn), and selenium (Se) levels decreased as the severity of the disease worsened, while the iron (Fe), and copper (Cu) levels were similar to the mild group and the control group, and the levels decreased as the disease worsened. It has also been found that vitamin D levels decrease as the severity of the disease worsens. Compared to the control group, TNF-α, MCP-1, and IFN-γ levels were found to decrease as the severity of the disease worsened. Also, it was observed that there was a significant relationship between essential metal levels and disease progression in most of the patient groups.
Decreased serum vitamin D level as a prognostic marker in patients with COVID-19

Ruyi Qu,Qiuji Yang,Yingying Bi,Jiajing Cheng,Mengna He,Xin Wei,Yiqi Yuan,Yuxin Yang,Jinlong Qin

DOI: https://doi.org/10.48550/arXiv.2301.02660

2022-12-25

Tissues and Organs

Abstract:Background: The corona virus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2, is still localized outbreak and has resulted in a high rate of infection and severe disease in older patients with comorbidities. The vitamin D status of the population has been found to be an important factor that could influence outcome of COVID-19. However, whether vitamin D can lessen the symptoms or severity of COVID-19 still remains controversial. Methods: A total of 719 patients with confirmed COVID-19 were enrolled retrospectively in this study from April 13 to June 6, 2022 at Shanghai Forth People's Hospital. The circulating levels of 25(OH)D3, inflammatory factors, and clinical parameters were assayed. Time to viral RNA clearance (TVRC), classification and prognosis of COVID-19 were used to evaluate the severity of COVID-19 infection. Results: The median age was 76 years (interquartile range, IQR, 64.5-84.6), 44.1% of patients were male, and the TVRC was 11 days (IQR, 7-16) in this population. The median level of 25(OH)D3 was 27.15 (IQR, 19.31-38.89) nmol/L. Patients with lower serum 25(OH)D3 had prolonged time to viral clearance, more obvious inflammatory response, more severe respiratory symptoms and higher risks of impaired hepatic and renal function. Multiple regression analyses revealed that serum 25(OH)D3 level was negatively associated with TVRC independently. ROC curve showed the serum vitamin D level could predict the severity classification and prognosis of COVID-19 significantly.Conclusions: Serum 25(OH)D3 level is independently associated with the severity of COVID-19 in elderly, and it could be used as a predictor of the severity of COVID-19. In addition, supplementation with vitamin D might provide beneficial effects in old patients with COVID-19.
Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers

Anshul Jain,Rachna Chaurasia,Narendra Singh Sengar,Mayank Singh,Sachin Mahor,Sumit Narain

DOI: https://doi.org/10.1038/s41598-020-77093-z

IF: 4.6

2020-11-19

Scientific Reports

Abstract:Abstract COVID-19 is characterized by marked variability in clinical severity. Vitamin D had recently been reviewed as one of the factors that may affect the severity in COVID-19. The objective of current study is to analyze the vitamin D level in COVID-19 patients and its impact on the disease severity. After approval from Ethics Committee, M.L.B Medical College the current study was undertaken as continuous prospective observational study of 6 weeks. Participants were COVID-19 patients of age group 30–60 years admitted during the study period of 6 weeks. Study included either asymptomatic COVID-19 patients (Group A) or severely ill patients requiring ICU admission (Group B). Serum concentration of 25 (OH)D, were measured along with serum IL-6; TNFα and serum ferritin. Standard statistical analysis was performed to analyze the differences. Current Study enrolled 154 patients, 91 in Group A and 63 patients in Group B. The mean level of vitamin D (in ng/mL) was 27.89 ± 6.21 in Group A and 14.35 ± 5.79 in Group B, the difference was highly significant. The prevalence of vitamin D deficiency was 32.96% and 96.82% respectively in Group A and Group B. Out of total 154 patients, 90 patients were found to be deficient in vitamin D (Group A: 29; Group B: 61). Serum level of inflammatory markers was found to be higher in vitamin D deficient COVID-19 patients viz. IL-6 level (in pg/mL) 19.34 ± 6.17 vs 12.18 ± 4.29; Serum ferritin 319.17 ± 38.21 ng/mL vs 186.83 ± 20.18 ng/mL; TNFα level (in pg/mL) 13.26 ± 5.64 vs 11.87 ± 3.15. The fatality rate was high in vitamin D deficient (21% vs 3.1%). Vitamin D level is markedly low in severe COVID-19 patients. Inflammatory response is high in vitamin D deficient COVID-19 patients. This all translates into increased mortality in vitamin D deficient COVID-19 patients. As per the flexible approach in the current COVID-19 pandemic authors recommend mass administration of vitamin D supplements to population at risk for COVID-19.

multidisciplinary sciences
Effect of vitamin D supplementation on clinical outcomes in adult patients with COVID‐19: A GRADE‐assessed systematic review and meta‐analysis of randomized controlled trials

Zohreh‐al‐sadat Ghoreshi,Javad Charostad,Nasir Arefinia,Mohsen Nakhaie,Mohammad Rezaei Zadeh Rukerd,Faranak Salajegheh

DOI: https://doi.org/10.1002/prp2.70013

2024-10-02

Pharmacology Research & Perspectives

Abstract:Selection process for eligible studies from all citations. The COVID‐19 pandemic has emerged as a major global health crisis. Vitamin D, a crucial fat‐soluble vitamin, has been recommended for COVID‐19 patients, though evidence of its effectiveness is inconsistent. This systematic literature review and meta‐analysis aimed to evaluate the impact of vitamin D supplementation on COVID‐19‐related outcomes. A comprehensive search was conducted across PubMed, Scopus, Web of Science, Embase, and Cochrane databases. Primary outcomes included mortality and hospital length of stay, while secondary outcomes encompassed C‐reactive protein (CRP), ferritin, D‐dimer, hemoglobin (Hb) concentrations, and lymphocyte, neutrophil, and platelet counts. Data analysis was performed using StataTM Version 14. A total of 16 trials were analyzed. The meta‐analysis revealed that vitamin D supplementation significantly reduced hospital length of stay (mean difference = −1.16; 95% confidence interval [CI]: −2.23, −0.09; p = .033) with significant heterogeneity (I2 = 69.2%, p = .002). Subgroup analysis showed a more pronounced reduction in studies with vitamin D dosages ≤10 000 international units (IU) (mean difference = −1.27; 95% CI: −1.96, −0.57; p 60 years) (mean difference = −1.13; 95% CI: −2.07, −0.18; p = .019). No significant changes were found in ferritin, D‐dimer, Hb concentrations, or in lymphocyte, neutrophil, and platelet counts (p > .05). In conclusion, while vitamin D supplementation did not significantly affect most COVID‐19‐related biomarkers, however, it reduces the length of hospital stay.

pharmacology & pharmacy
Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis

Christiano Argano,Raffaella Mallaci Bocchio,Giuseppe Natoli,Salvatore Scibetta,Marika Lo Monaco,Salvatore Corrao

DOI: https://doi.org/10.3390/ph16010130

IF: 4.6

2023-01-17

Pharmaceuticals

Abstract:Background: The COVID-19 pandemic represents one of the world's most important challenges for global public healthcare. Various studies have found an association between severe vitamin D deficiency and COVID-19-related outcomes. Vitamin D plays a crucial role in immune function and inflammation. Recent data have suggested a protective role of vitamin D in COVID-19-related health outcomes. The purpose of this meta-analysis and trial sequential analysis (TSA) was to better explain the strength of the association between the protective role of vitamin D supplementation and the risk of mortality and admission to intensive care units (ICUs) in patients with COVID-19. Methods: We searched four databases on 20 September 2022. Two reviewers screened the randomized clinical trials (RCTs) and assessed the risk of bias, independently and in duplicate. The pre-specified outcomes of interest were mortality and ICU admission. Results: We identified 78 bibliographic citations. After the reviewers' screening, only five RCTs were found to be suitable for our analysis. We performed meta-analyses and then TSAs. Vitamin D administration results in a decreased risk of death and ICU admission (standardized mean difference (95% CI): 0.49 (0.34–0.72) and 0.28 (0.20–0.39), respectively). The TSA of the protective role of vitamin D and ICU admission showed that, since the pooling of the studies reached a definite sample size, the positive association is conclusive. The TSA of the protective role of vitamin D in mortality risk showed that the z-curve was inside the alpha boundaries, indicating that the positive results need further studies. Discussion: The results of the meta-analyses and respective TSAs suggest a definitive association between the protective role of vitamin D and ICU hospitalization.

pharmacology & pharmacy,chemistry, medicinal

Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey

Serum 25-hydroxyvitamin D levels and health outcomes of hospitalization owing to COVID-19: a retrospective cross-sectional study

The relationship between vitamin D deficiency and mortality in older adults before and during COVID-19 pandemic

Serum vitamin D levels and the severity and clinical course of COVID-19

The Impact of Serum Levels of Vitamin D3 and Its Metabolites on the Prognosis and Disease Severity of COVID-19

Vitamin D supplementations and mortality among patients with moderate/severe COVID-19: A meta-analysis of randomized controlled trials

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection

Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1

Association of Vitamin D Status and COVID-19-Related Hospitalization and Mortality

The impact of vitamin D administration on mortality in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials

Serum Vitamin D Concentrations and Covid-19 In Pregnant Women, Does Vitamin D Supplementation Impact Results? A Comprehensive Study

Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection

Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients

The role of vitamin D in outcomes of critical care in COVID-19 patients: Evidence from an umbrella meta-analysis of interventional and observational studies

Impact of Vitamin D Therapy on the Progress COVID-19: Six Weeks Follow-Up Study of Vitamin D Deficient Elderly Diabetes Patients

Risk factors for infection and mortality among hemodialysis patients during COVID-19 pandemic

Effects of Immunotoxicity biomarkers, essential elements and vitamin D levels on the severity levels of COVID-19 disease in Turkey

Decreased serum vitamin D level as a prognostic marker in patients with COVID-19

Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers

Effect of vitamin D supplementation on clinical outcomes in adult patients with COVID‐19: A GRADE‐assessed systematic review and meta‐analysis of randomized controlled trials

Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis